Twan Sia, Leeon Bacchus, Riki Tanaka, Raisa Khuda, Shibani Mallik, John Leung
Clinical and translational gastroenterology, Sep 27, 2023
INTRODUCTION: Non-eosinophilic esophagitis eosinophilic gastrointestinal disorders (non-EoE-EGIDs) have limited treatment options to induce histologic and clinical remission. Dupilumab is a human monoclonal antibody against the interleukin-4 receptor ɑ subunit, which has been reported to induce improvement in pediatric patients with non-EoE-EGIDs. METHODS: We conducted a retrospective chart review to identify if patients with eosinophilic gastritis (EoG) and/or eosinophilic duodenitis (EoD) experience clinical and histologic remission with dupilumab. RESULTS: Twelve patients were included (2 patients with EoG and EoD, 4 patients with EoG only, and 6 patients with EoD only). All patients experienced improvement of at least one symptom on dupilumab, 3 patients (25%) had no change in severity of one or more of their symptoms, and no patients had worsening symptoms. On dupilumab, 2 EoG patients (40%) and 3 EoD patients (33.3%) were completely asymptomatic. Histologic changes were investigated in a subanalysis including 8 patients (2 patients with EoG and EoD, 2 patients with EoG only, and 4 patients with EoD only). Median peak gastric eosinophil counts in EoG patients reduced from 80.5 eos/hpf (min-max 32-150, Q1-Q3 45.5-111) to 7.5 eos/hpf (min-max 0-28, Q1-Q3 1.5-16.8). Median peak duodenal eosinophil counts in EoD patients reduced from 39 eos/hpf (min-max 30-50, Q1-Q3 37.3-46.3) to 16.5 eos/hpf (min-max 30-50, Q1-Q3 37.3-46.3). All 4 patients (100%) with EoG, and 4 patients (66.6%) with EoD had histologic remission on dupilumab. DISCUSSION: In this retrospective case series, we show preliminary evidence that dupilumab may be effective in inducing histologic and symptomatic remission in patients with non-EoE-EGIDs.